Introduction
============

Familial adenomatous polyposis is characterized by the appearance of numerous polyps in the large intestine. Untreated polyps lead to the development of colorectal cancer before age 50 years. The correlation between mutations of the *APC*gene and the occurrence of familial adenomatous polyposis was described in 1991 \[[@B1],[@B2]\] and since then mutations of the *APC*gene have been investigated in many research centres identifying various types of mutations. In the case of the largest group, comprising 1,164 families from Germany, mutations were identified in 54% of families \[[@B3]\].

The latest investigations point to a correlation between homozygotic mutations of the *MYH*gene alleles and the occurrence of the recessive form of polyposis of the large intestine. The product of the *MYH*gene is an endonuclease of the DNA repair system by way of base excision and recognises non-pairings of the A/G, A/GO and A/C types \[[@B4]\]. The defect of both gene alleles gives a status of somatic mutations of the *APC*gene in the form of G:C \> T:A pairs which change GAA codons into TAA. The *APC*gene is particularly sensitive to the appearance of mutations developing as a result of the lack of functions in the *MYH*locus because 216 GAA codons occur in it \[[@B5]\]. The *MYH*gene is located on chromosome 1p32-34, consists of 16 exons and encompasses 7,100 base pairs \[[@B5]\]. The two most common mutations, Y165C and G382D, which occur in the European population with a frequency of 1%, are observed in 80% patients with mutations of both alleles of the *MYH*gene \[[@B6]-[@B8]\]. Data concerning the phenotype of mutation carriers in the *MYH*gene are not very extensive. In the majority, the described mutation carriers in the *MYH*gene are characterized by a milder course of the disease and a smaller number of polyps than is the case in the classic FAP. The phenotype is similar to attenuated adenomatous polyposis of the colon (AAPC) and the number of polyps does not exceed 1,000. Homozygous mutations of the *MYH*gene are associated with the occurrence of the disease in 8% of patients in whom mutations in the *APC*gene have not been discovered \[[@B6]\].

In samples collected in our DNA bank of families with FAP, mutations were identified in 50% of families \[[@B9]\]. In the course of this study, 90 FAP patients with no mutation identified in the *APC*gene were examined with regard to the occurrence of mutations in the *MYH*gene using the PCR-HD and PCR-SSCP methods to investigate the coding sequence of the *APC*gene. We determined the frequency occurrence of the G382M and Y165C mutations as well as the V22M polymorphism described earlier.

Patients and methods
====================

The examined group comprised patients with diagnosed large intestine polyposis derived from the DNA bank of patients with familial polyposis from the Institute of Human Genetics, Polish Academy of Sciences in Poznań. The group of 90 patients with no mutation identified in the *APC*gene derived from different parts of Poland. The age when the first disease symptoms occurred ranged from 10 to 50 years with an average age of 29.5 at symptom appearance. In the examined group, 12 cases occurred in the studied families *de novo*(typical FAP phenotype), 16 patients represented cases of the attenuated form of the disease with a small number of polyps, and the remainding were cases of the classical form of familial polyposis with the number of polyps exceeding 1,000.

Molecular methods
=================

DNA was extracted from peripheral blood cells by the classical phenol purification method. The *MYH*gene fragments were amplified using primers and PCR reaction condition as previously described by Al-Tassan \[[@B10]\]. The amplified fragments of the *MYH*gene were screened for mutations using heteroduplex analysis (HD) and single strand conformational polymorphism (SSCP) methods \[[@B11]\]. DNA fragments showing heteroduplex in HD analysis or additional pattern in SSCP analysis were subjected to direct PCR product sequencing and analysed using the Perking Elmer ABI 377 DNA sequencer according to the manufacturer\'s specifications. For V22M screening, the PCR product of exon 2 of the MYH gene was digested with -Nco I endonuclease. Exons 7 and 13 were screened for Y165C and G382D variants using the DHPLC method. The amplified fragments were denatured at 95°C for 5 min. and slowly annealed from 95°C to 65°C over 30 min. to promote heteroduplex formation. The PCR products were injected into the column and eluted using an increasing acetonitryle gradient. The conditions distinguishing the Y165C (exon 7) and the G382D (exon 13) variants were established, Figure [1](#F1){ref-type="fig"}. The DHPLC parameters for those separations are presented in Table [1](#T1){ref-type="table"}.

![**Flourograms of DHPLC analysis of *MYH*gene**. A. Exon 7 of *MYH*gene, grey negative control, black Y165C; B. Exon 13 of *MYH*gene, grey negative control, black D382G](1897-4287-4-1-43-1){#F1}

###### 

DHPLC conditions for analyses of exons 7 and 13 of the *MYH*gene

  Exon 7 (Y165C)                                                           
  --------------------- ---------------- ---------------- ---------------- ----------------
                        **Time (min)**   **% Buffer A**   **% Buffer B**   **Oven temp**.
                                                                           
  loading               0.0              55.9             44.1             62.8°C
                                                                           
  start gradient        0.5              50.9             49.1             
                                                                           
  stop gradient         5.0              41.9             58.1             
                                                                           
  **Exon 13 (G382D)**                                                      
                                                                           
                        **Time (min)**   **%A**           **AB**           
                                                                           
  loading               0.0              53.9             46.1             65.6°C
                                                                           
  start gradient        0.5              48.5             51.5             
                                                                           
  stop gradient         5.0              39.9             60.1             

Buffer A: 50 ml M TEAA, 250 μl AcN → 1 L H~2~0

Buffer B: 50 ml M TEAA, 250 ml AcN → 1 L H~2~0

Results and discussion
======================

96 probands without mutation in the *APC*gene were examined for the occurrence of mutation in the *MYH*gene. The main emphasis in the performed studies was placed on the frequency of occurrence of the already described pathogenic substitutions Y165C and G382D. For easy variant identification, conditions of the DHPLC examination were optimized for the above two mutations. The third variant, V22M, which is not considered pathogenic, was examined using restriction analysis. In the examined group, 9 cases of G382C substitution, 4 cases of Y165C and 5 cases of V22M were recorded.

Examination of the *MYH*gene coding sequence using PCR-HD and PCR-SSCP methods led to the conclusion that the *MYH*gene did not contain polymorphic variants in the remaining part of the coding sequence. The above-mentioned frequent mutations failed to occur as homozygous (Table [2](#T2){ref-type="table"}). One of the carriers of the Y165C mutation with the classical form of familial polyposis was also the carrier of the G169D mutation in the second allele of the *MYH*gene. G169D is a novel change in the *MYH*gene not described before. A change in amino acid sequence can lead to a phenotypic effect but the pathogenicity of this variant cannot be determined at this stage. This mutation is also observed in the patient\'s brother with clinical symptoms and phenotype of classical form of FAP. In the case of both affected brothers, numerous polyps were observed to appear in the fourth decade of their lives. In 12 persons in whom one of the pathogenic mutations occurred, the mild form of the disease was diagnosed in 3 cases, whereas in 9 cases the diagnosed form was that of classical FAP. The age of appearance of the disease in this group was quite low and the youngest patients were only 12 years old when the first symptoms of the disease were identified. The percentage of the mild form of the polyposis did not differ significantly from the frequency observed in the entire examined group. The phenotype of the classical form of the disease observed in this group failed to correlate with the earlier observations about the milder course of the disease in the carriers of homozygotic mutation in the *MYH*gene \[[@B10],[@B12]\]. This observation reveals the absence of predisposition to the disease by mutations in the *MYH*gene in the homozygotic system as confirmed by screening for the mutation using PCR-HD and PCR-SSCP methods. In addition, the average age of occurrence of the disease in the group in which one of the pathogenic mutations or the V22M polymorphism occur is by 10 years lower than in the entire examined population. It is true that the size of the examined group is not big, but it cannot be excluded that these mutations may have a modifying effect on other genetic factors predisposing to the disease. The results indicate that in our group of patients with diagnosed FAP without mutation in the *APC*gene, the proportion of the mutation in the *MYH*gene exerts a very small effect on preconditioning the disease.

###### 

Genetic variants observed in the *MYH*gene in Polish FAP patients

  **No**.   Proband   Mutation          Genetic variant   Phenotype
  --------- --------- ----------------- ----------------- -----------
  1         9039      494A\>G 506G\>A   Y165C G169D       FAP
                                                          
  2         9121      494A\>G           Y165C             FAP
                                                          
  3         9160      494A\>G           Y165C             FAP
                                                          
  4         9164      494A\>G           Y165C             FAP
                                                          
  5         9056      1145G\>A          G382D             AFAP
                                                          
  6         9101      1145G\>A          G382D             FAP
                                                          
  7         9109      1145G\>A          G382D             FAP
                                                          
  8         9113      1145G\>A          G382D             FAP
                                                          
  9         9120      1145G\>A          G382D             FAP
                                                          
  10        9132      1145G\>A          G382D             FAP
                                                          
  11        9133      1145G\>A          G382D             AFAP
                                                          
  12        9140      1145G\>A          G382D             AFAP
                                                          
  13        9157      1145G\>A          G382D             FAP
                                                          
  14        9052      64G\>A            V22M              FAP
                                                          
  15        9054      64G\>A            V22M              FAP
                                                          
  16        9055      64G\>A            V22M              FAP
                                                          
  17        9072      64G\>A            V22M              FAP
                                                          
  18        9163      64G\>A            V22M              AFAP

This situation may be associated with the fact that our physicians may use more stringent criteria in the course of qualifications for examinations than doctors in other groups. The stringent criteria used in the qualification of patients as having FAP syndrome may be one explanation of the above observations.
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